GSK plc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 GSK plc 公司

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

GSK plc簡介



公司代碼GSK

公司名稱GSK plc

上市日期May 22, 1972

CEOWaterhouse (Deborah)

員工數量68629

證券類型Depository Receipt

年結日May 22

公司地址980 Great West Road

城市BRENTFORD

上市交易所NASDAQ OMX NASDAQ Basic NYSE

國家United Kingdom

郵編TW8 9GS

電話442080475000

網址https://www.gsk.com/

公司代碼GSK

上市日期May 22, 1972

CEOWaterhouse (Deborah)

GSK plc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Hal V. Barron, M.D.

Non-Executive Director

602.15K

+0.00%

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

514.11K

+0.12%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

41.23K

+0.76%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

3.45K

+0.75%

Dr. Jeannie Lee

Independent Non-Executive Director and Scientific & Medical Expert

2.00K

+0.70%

Mr. David S. Redfern

President - Corporate Development

--

Ms. Victoria Anne Whyte

Company Secretary

--

Mr. Phil C. Thomson

President - Global Affairs

--

Dame Emma N. Walmsley

Chief Executive Officer, Executive Director

--

Mr. Luke Miels

Chief Executive Officer - Designate, Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Hal V. Barron, M.D.

Non-Executive Director

602.15K

+0.00%

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

514.11K

+0.12%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

41.23K

+0.76%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

3.45K

+0.75%

Dr. Jeannie Lee

Independent Non-Executive Director and Scientific & Medical Expert

2.00K

+0.70%

Mr. David S. Redfern

President - Corporate Development

--

收入明細

單位: USD更新時間: 4月6日週一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

HIV

10.12B

23.53%

Respiratory

9.31B

21.64%

Immuno-inflammation

5.02B

11.66%

Shingles

4.69B

10.89%

Established Vaccines

4.11B

9.55%

其他

9.78B

22.73%

地區USD

名稱

營收

佔比

US

22.20B

51.61%

Rest of world

10.90B

25.33%

Europe

9.92B

23.06%

業務

地區

業務USD

名稱

營收

佔比

HIV

10.12B

23.53%

Respiratory

9.31B

21.64%

Immuno-inflammation

5.02B

11.66%

Shingles

4.69B

10.89%

Established Vaccines

4.11B

9.55%

其他

9.78B

22.73%

股東統計

更新時間: 5月7日週四

持股股東

股東類型

持股股東

佔比

Dodge & Cox

3.38%

Fidelity Management & Research Company LLC

2.81%

Fisher Investments

1.70%

PRIMECAP Management Company

1.24%

JTC Employer Solutions Trusteee Ltd

0.71%

其他

90.16%

持股股東

佔比

Dodge & Cox

3.38%

Fidelity Management & Research Company LLC

2.81%

Fisher Investments

1.70%

PRIMECAP Management Company

1.24%

JTC Employer Solutions Trusteee Ltd

0.71%

其他

90.16%

股東類型

持股股東

佔比

Investment Advisor

9.05%

Investment Advisor/Hedge Fund

8.17%

Research Firm

1.01%

Hedge Fund

0.92%

Pension Fund

0.13%

Bank and Trust

0.10%

Individual Investor

0.06%

Family Office

0.03%

Family Office

0.02%

其他

80.52%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q1

1585

393.46M

19.40%

-23.49M

2025Q4

1508

391.56M

19.21%

-21.81M

2025Q3

1474

388.63M

19.14%

-11.70M

2025Q2

1478

378.08M

18.54%

+5.70M

2025Q1

1494

378.46M

18.50%

+5.08M

2024Q4

1481

355.06M

17.14%

+27.38M

2024Q3

1472

319.97M

15.44%

-30.07M

2024Q2

1585

322.06M

15.54%

-29.11M

2024Q1

1617

318.91M

15.39%

-23.52M

2023Q4

1614

299.81M

14.57%

-35.71M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Dodge & Cox

68.52M

3.37%

-9.89M

-12.61%

Dec 31, 2025

Fidelity Management & Research Company LLC

56.97M

2.81%

+1.14M

+2.04%

Dec 31, 2025

Fisher Investments

33.20M

1.64%

+968.37K

+3.00%

Dec 31, 2025

PRIMECAP Management Company

25.13M

1.24%

-636.79K

-2.47%

Dec 31, 2025

JTC Employer Solutions Trusteee Ltd

14.43M

0.71%

-169.18K

-1.16%

Dec 31, 2025

Wellington Management Company, LLP

12.56M

0.62%

+9.14M

+267.14%

Dec 31, 2025

Acadian Asset Management LLC

8.96M

0.44%

+6.18M

+221.47%

Dec 31, 2025

Fidelity Institutional Asset Management

8.15M

0.4%

+179.23K

+2.25%

Dec 31, 2025

Holocene Advisors, LP

8.12M

0.4%

+1.02M

+14.31%

Dec 31, 2025

T. Rowe Price International Ltd

7.89M

0.39%

-56.47K

-0.71%

Dec 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

VanEck Pharmaceutical ETF

10.83%

The Opal International Dividend Income ETF

4.41%

Sound Equity Dividend Income ETF

3.97%

Keating Active ETF

3.88%

USCF Dividend Income Fund

3.83%

Brandes International ETF

2.87%

Altrius Global Dividend ETF

2.58%

Fidelity Blue Chip Value ETF

1.6%

Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF

1.17%

Avantis International Large Cap Value ETF

1.02%

VanEck Pharmaceutical ETF

佔比10.83%

The Opal International Dividend Income ETF

佔比4.41%

Sound Equity Dividend Income ETF

佔比3.97%

Keating Active ETF

佔比3.88%

USCF Dividend Income Fund

佔比3.83%

Brandes International ETF

佔比2.87%

Altrius Global Dividend ETF

佔比2.58%

Fidelity Blue Chip Value ETF

佔比1.6%

Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF

佔比1.17%

Avantis International Large Cap Value ETF

佔比1.02%

分紅派息



近5年累計派現 15.69B 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

May 04, 2026

GSK.NB Approximate interim Cash Dividend of gross USD 0.461074 paid on Jul 09, 2026 going ex on May 15, 2026

May 15, 2026

Jul 09, 2026

May 15, 2026

Apr 29, 2026

GSK.NB Interim Cash Dividend of gross paid on Jul 09, 2026 going ex on May 15, 2026

May 15, 2026

Jul 09, 2026

May 15, 2026

Feb 05, 2025

GSK.NB Interim Cash Dividend of gross USD 0.434774 paid on Jul 10, 2025 going ex on May 16, 2025

May 16, 2025

Jul 10, 2025

May 16, 2025

Feb 05, 2025

GSK.NB Interim Cash Dividend of gross USD 0.42996 paid on Oct 09, 2025 going ex on Aug 15, 2025

Aug 15, 2025

Oct 09, 2025

Aug 15, 2025

Feb 05, 2025

GSK.NB Approximate final Cash Dividend of gross USD 0.417088 paid on Jan 08, 2026 going ex on Nov 14, 2025

Nov 14, 2025

Jan 08, 2026

Nov 14, 2025

Feb 05, 2025

GSK.NB Interim Cash Dividend of gross USD 0.407568 paid on Apr 10, 2025 going ex on Feb 21, 2025

Feb 21, 2025

Apr 10, 2025

Feb 21, 2025

Feb 05, 2025

GSK.NB Approximate interim Cash Dividend of gross paid on Apr 09, 2026 going ex on Feb 20, 2026

Feb 20, 2026

Apr 09, 2026

Feb 20, 2026

Oct 30, 2024

GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024

Nov 15, 2024

Jan 09, 2025

Nov 15, 2024

Jul 31, 2024

GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Oct 10, 2024

Aug 16, 2024

May 01, 2024

GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024

May 17, 2024

Jul 11, 2024

May 16, 2024

拆合股



公告日期

除權除息日

類型

比率

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

公告日期

除權除息日

類型

比率

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4